Integer Holdings Faces Class Action with Lead Plaintiff Deadline on February 9, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Class Action Notification: Rosen Law Firm reminds investors who purchased Integer common stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Integer materially overstated its competitive position in the electrophysiology market and failed to disclose a sustained deterioration in sales of two of its EP devices, resulting in investor losses.
- Choosing Counsel: Rosen Law Firm emphasizes the importance of selecting experienced legal counsel, noting that many firms issuing notices lack the necessary resources and experience to effectively represent clients in litigation.
- Historical Performance: The firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong capabilities in securities litigation.
ITGR
$78.58+Infinity%1D
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 78.520
Low
69.00
Averages
91.75
High
140.00
Current: 78.520
Low
69.00
Averages
91.75
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
